The aim of this study was to evaluate the therapeutic effects of chlorogenic acid (CGA) in rats with advanced alcoholic steatohepatitis. The rats were fed on a high-fat diet and gavaged with ethanol (4 g/kg) for 8 weeks. The livers of ethanol-treated rats showed steatosis; necrosis and mononuclear infiltration; and significant upregulation of the mRNA expression of the prooxidant (Cyp2e1, iNos), lipogenic (Srebp1, Acc), proinflammatory (Tlr4, Nf-κb, TnfA, Il-1B, and Il-6), and profibrogenic (TgfB, Col1, VegfA) genes. Simultaneously, a downregulation of level of Sod and Nrf2 was observed, which was accompanied by increased serum transaminase, TnfA, and serum and liver triglycerides levels. CGA administration (40 and 80 mg/kg, 8 weeks) to ethanol-fed group reduced the liver expression levels of Cyp2e1 and iNos, whereas it markedly enhanced the expression of Sod, Nrf2, and Ho-1. CGA at both doses downregulated the expressions of lipogenic, proinflammatory, and profibrogenic genes, while the expression of Tlr4 was lowered only after the higher dose of CGA. The higher dose of CGA efficiently prevented the progression of alcohol-induced steatosis and reduced inflammation through regulation of the expression of genes encoding the proteins involved in the Tlr4/Nf-κB signaling pathway and fibrosis. The study revealed hepatoprotective and anti-inflammatory effects of CGA through the regulation of expression of genes encoding Cyp2e1/Nrf2 involved in oxidative stress modulation. These results demonstrate CGA as a therapeutic candidate for the prevention and treatment of alcoholic steatohepatitis.
The purpose of this pilot study was to develop and characterize an in vivo porcine model of oxalate-induced renal injury using intravenous infusion of sodium oxalate (NaOx). 2 experimental regimens were developed to replicate acute and chronic hyperoxaluria. In the acute model, 3 different doses of 1% NaOx were administered over 15 hours, resulting in a dose-dependent increase in plasma oxalate concentration (Cmax: 42.4-122.4 µM) and transient hyperoxaluria, with a return to baseline values 6-8 hours after stopping the infusion of NaOx solution. In the chronic model, repeated infusions of NaOx for 7-11 days led to persistent hyperoxalemia (up to 302.4 µM), decreased appetite and increasing renal failure. Histological analysis revealed dose-dependent calcium oxalate (CaOx) deposits in renal tissue (1.85%-9.55% of renal surface area), consistent with moderate to severe nephrocalcinosis. The model represents the key clinical features of both acute kidney injury and the progressive nephrocalcinosis observed in primary hyperoxaluria and oxalaturia. Due to the physiological similarity between pigs and humans, the proposed porcine model is valuable for studying the pathophysiology of oxalate excess and for testing the efficacy of new therapies to counteract its toxicity.